We have located links that may give you full text access.
Comparison of standard-dose and half-dose dual-source abdominopelvic CT scans for evaluation of acute abdominal pain.
Acta Radiologica 2018 October 31
BACKGROUND: With the increasing number of computed tomography (CT) scans used for evaluation of acute abdominal pain, patient radiation exposure has increased rapidly.
PURPOSE: To determine whether the diagnostic performance of half-dose abdominopelvic CT is non-inferior to that of standard-dose CT for patients with acute abdominal pain.
MATERIAL AND METHODS: Ninety-eight patients with acute abdominal pain underwent dual-source abdominopelvic CT. Three sets of CT images were reconstructed: standard-dose filtered back projection (FBP); half-dose FBP; and half-dose sinogram-affirmed iterative reconstruction (SAFIRE3 ). Diagnostic performance of the standard-dose scan was compared with that of the half-dose scans by using a non-inferiority test with a 10% margin. The overall image quality was subjectively measured.
RESULTS: Diagnostic performance for overall disease diagnosis with half-dose scans (area under the receiver operating characteristic curve [AUC] = 0.835 for FBP, 0.881 for SAFIRE3 ) was non-inferior to that of standard-dose FBP (AUC = 0.891) (95% confidence interval lower limit difference = -5.6% [half-dose FBP], -1.2% [half-dose SAFIRE3 ]). The diagnostic sensitivity for detection of neoplastic disease was lower with half-dose (75.0%) than with standard-dose FBP (91.7%). Effective dose and dose-length product with standard-dose imaging were 7.99 ± 2.55 mSv and 533.1 ± 170.3 mGy·cm, respectively; those of half-dose imaging were 3.99 ± 1.28 mSv and 266.6 ± 85.2 mGy·cm, respectively. The image quality was lower with half-dose than with standard-dose FBP scans ( P < 0.01).
CONCLUSION: Diagnostic performance of half-dose CT is non-inferior to that of standard-dose scan for evaluation of acute abdominal pain, despite inferior image quality.
PURPOSE: To determine whether the diagnostic performance of half-dose abdominopelvic CT is non-inferior to that of standard-dose CT for patients with acute abdominal pain.
MATERIAL AND METHODS: Ninety-eight patients with acute abdominal pain underwent dual-source abdominopelvic CT. Three sets of CT images were reconstructed: standard-dose filtered back projection (FBP); half-dose FBP; and half-dose sinogram-affirmed iterative reconstruction (SAFIRE3 ). Diagnostic performance of the standard-dose scan was compared with that of the half-dose scans by using a non-inferiority test with a 10% margin. The overall image quality was subjectively measured.
RESULTS: Diagnostic performance for overall disease diagnosis with half-dose scans (area under the receiver operating characteristic curve [AUC] = 0.835 for FBP, 0.881 for SAFIRE3 ) was non-inferior to that of standard-dose FBP (AUC = 0.891) (95% confidence interval lower limit difference = -5.6% [half-dose FBP], -1.2% [half-dose SAFIRE3 ]). The diagnostic sensitivity for detection of neoplastic disease was lower with half-dose (75.0%) than with standard-dose FBP (91.7%). Effective dose and dose-length product with standard-dose imaging were 7.99 ± 2.55 mSv and 533.1 ± 170.3 mGy·cm, respectively; those of half-dose imaging were 3.99 ± 1.28 mSv and 266.6 ± 85.2 mGy·cm, respectively. The image quality was lower with half-dose than with standard-dose FBP scans ( P < 0.01).
CONCLUSION: Diagnostic performance of half-dose CT is non-inferior to that of standard-dose scan for evaluation of acute abdominal pain, despite inferior image quality.
Full text links
Related Resources
Trending Papers
Autoimmune Hemolytic Anemias: Classifications, Pathophysiology, Diagnoses and Management.International Journal of Molecular Sciences 2024 April 13
Executive Summary: State-of-the-Art Review: Unintended Consequences: Risk of Opportunistic Infections Associated with Long-term Glucocorticoid Therapies in Adults.Clinical Infectious Diseases 2024 April 11
Clinical practice guidelines on the management of status epilepticus in adults: A systematic review.Epilepsia 2024 April 13
Finerenone: From the Mechanism of Action to Clinical Use in Kidney Disease.Pharmaceuticals 2024 March 27
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app